packageTisagenlecleucel

tisagenlecleucel

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Tisagenlecleucel is a cell and gene therapy used to treat certain B-cell blood cancers, including B-cell acute lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma. It is an approved medicine authorised in the European Union, and is also being studied for other uses.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:tisagenlecleucel
ATC codes:L01XL04
DrugBank:DB13881

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown